Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial, Lancet Oncol, vol.17, pp.1248-1260, 2016. ,
URL : https://hal.archives-ouvertes.fr/inserm-01407426
Profile of vemurafenib-induced severe skin toxicities, J Eur Acad Dermatol Venereol, vol.30, pp.250-257, 2016. ,
URL : https://hal.archives-ouvertes.fr/inserm-01819814
Case of vemurafenib-induced Sweet's syndrome, J Dermatol, vol.41, pp.817-820, 2014. ,
Sweet syndrome following vemurafenib therapy for recurrent cholangiocarcinoma, J Cutan Pathol, vol.41, pp.326-328, 2014. ,
Neutrophilic eccrine hidradenitis in two patients treated with BRAF inhibitors: a new cutaneous adverse event, Br J Dermatol, vol.176, pp.1645-1648, 2017. ,
Panniculitis with arthralgia in patients with melanoma treated with selective BRAF inhibitors and its management, Arch Dermatol, vol.148, pp.357-361, 2012. ,
Panniculitis with necrotizing granulomata in a patient on BRAF inhibitor (dabrafenib) therapy for metastatic melanoma, Am J Dermatopathol, vol.37, pp.96-99, 2015. ,
Cutaneous granulomatous panniculitis and sarcoidal granulomatous papular eruption in a patient with metastatic melanoma treated with a BRAF inhibitor, J Dermatol, vol.43, pp.715-716, 2016. ,
Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma, Br J Dermatol, vol.167, pp.1153-1160, 2012. ,
Erythema nodosum-like lesions during BRAF inhibitor therapy: report on 16 new cases and review of the literature, J Eur Acad Dermatol Venereol, vol.29, pp.1797-1806, 2015. ,